Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib toward primary CLL cells

Vitale Candida; Todaro Maria; Griggio Valentina; Salvetti Chiara; Riganti Chiara; Landesman Yosef; Boccadoro Mario; Coscia Marta

首页> 外文期刊>Leukemia and lymphoma >Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib toward primary CLL cells

【24h】

Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib toward primary CLL cells

机译：与化疗或伊尔替尼替氏菌与初级CLL细胞组合的细胞毒性作用评价

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia and lymphoma 》 |2020年第s1期| 共2页
作者
Vitale Candida; Todaro Maria; Griggio Valentina; Salvetti Chiara; Riganti Chiara; Landesman Yosef; Boccadoro Mario; Coscia Marta;
展开▼
作者单位

AOU Citta Salute &

Sci Torino Div Hematol Turin Italy;

Univ Torino Turin Italy;

Univ Torino Dept Mol Biotechnol &

Hlth Sci Turin Italy;

Univ Torino Turin Italy;

Univ Torino Dept Oncol Turin Italy;

Karyopharm Therapeut Inc Newtown PA USA;

Univ Torino Turin Italy;

Univ Torino Turin Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib toward primary CLL cells [J] . Vitale Candida, Todaro Maria, Griggio Valentina, Leukemia and lymphoma . 2020 ,第S1期

机译：与化疗或伊尔替尼替氏菌与初级CLL细胞组合的细胞毒性作用评价
2. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment [J] . S Betrian, L Ysebaert, K H Heider, Blood cancer journal. . 2016 ,第11期

机译：依达拉西布改善CD37抗体BI 836826对化学抗性/复发性CLL细胞的细胞毒性：联合治疗的基本原理
3. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. [J] . Aneel Paulus, Aisha Masood, Kena C Miller, British Journal of Haematology . 2014 ,第1期

机译：研究药物MLN2238可以作为单一药物并与其他药物联合使用，在体外诱导细胞凋亡并对CLL细胞具有细胞毒性。
4. Comparison Of The Combination (Paclitaxel+Fluorouracil+Doxorubucin) And Single Drug Chemotherapy Against Primary Breast Cancer Cells [C] . Kadriye Ciftci, Anshul Gupte, Stuart Madden Annual meeting exposition of the Controlled Release Society . 2005

机译：紫杉醇+氟尿嘧啶+阿霉素联合治疗与单药化疗对原发性乳腺癌细胞的比较
5. Perturbing the epigenome: Effects of folate pathway disruptions and combination chemotherapy treatment on male germ cells. [D] . Chan, Donovan. 2012

机译：扰动表观基因组：叶酸途径破坏和联合化疗对男性生殖细胞的影响。
6. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment [O] . S Betrian, L Ysebaert, K H Heider, 2016

机译：依达拉西布改善CD37抗体BI 836826对化学抗性/复发型CLL细胞的细胞毒性：联合治疗的基本原理
7. Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller/T-cell lymphoma. [O] . Tiffany Tang, Peter Martin, Nagavalli Somasundaram, 2020

机译：I阶段研究Selinexor与地塞米松，Ifosfamide，Carboplatin，复发或难治性外周T细胞或Naturalkiller / T细胞淋巴瘤患者的依托普齐德化疗。
8. Breaking Cancer Dormancy to Sensitize Dormant Breast Cancer Cells to Cytotoxic Chemotherapy. [R] . Tran, D. 2012

机译：打破癌症休眠，使休眠乳腺癌细胞对细胞毒性化疗敏感。

Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib toward primary CLL cells

著录项

相似文献

相关主题

期刊订阅